Prothena Corporation plc is a clinical-stage
         biotechnology company with a portfolio of
      novel monoclonal antibodies that may offer new
   treatments for diseases associated with protein
misfolding or cell adhesion.

LATEST NEWS

LATEST PROTHENA INFORMATION

SPOTLIGHT

Potential Mechanism of Action (MOA) Videos:

vid_neod001
for Amyloidosis
vid_prx002
for Parkinson’s Disease
vid_prx003
for Inflammatory Diseases
and Cancers

thumbnail-bloomberg-daleCEO Dale Schenk discusses Prothena’s proprietary programs with Bloomberg TV
Discusses development of treatments for Alzheimer’s and Parkinson’s diseases with Olivia Sterns on Bloomberg’s “In the Loop”.  June 6, 2013